Commonwealth Equity Services’s Zevra Therapeutics ZVRA Stock Holding History

Commonwealth Equity Services’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189K	Hold	13,184	–	–	﹤0.01%	4144
2026 Q1	$123K	Sell	13,184 -1,045	-7%	-$9.42K	﹤0.01%	4101
2025 Q4	$127K	Sell	14,229 -11,714	-45%	-$111K	﹤0.01%	4075
2025 Q3	$247K	Sell	25,943 -5,391	-17%	-$54.1K	﹤0.01%	3797
2025 Q2	$276K	Buy	31,334 +898	+3%	+$7.29K	﹤0.01%	3673
2025 Q1	$228K	Buy	30,436 +9	+0%	+$72	﹤0.01%	3732
2024 Q4	$254K	Hold	30,427	–	–	﹤0.01%	3566
2024 Q3	$211K	Buy	30,427 +1,199	+4%	+$8.14K	﹤0.01%	3650
2024 Q2	$143K	Buy	+29,228	New	+$138K	﹤0.01%	3737
2023 Q4	–	Sell	-10,858	Closed	-$52K	–	4033
2023 Q3	$52K	Buy	10,858 +858	+9%	+$4.28K	﹤0.01%	3657
2023 Q2	$51K	Buy	+10,000	New	+$53.9K	﹤0.01%	3662

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Commonwealth Equity Services's ZVRA Position: Q2 2026 in Review

Commonwealth Equity Services held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 13,184 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #4144.

Commonwealth Equity Services first reported a position in ZVRA in Q2 2023 and has held it in 11 quarters since. The position peaked at $276K in Q2 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Commonwealth Equity Services held 13,184 shares of Zevra Therapeutics worth $189K as of Q2 2026.
Commonwealth Equity Services left its Zevra Therapeutics share count unchanged in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4144 holding.
Commonwealth Equity Services first reported a position in Zevra Therapeutics in Q2 2023 and has held it in 11 quarters since.
Commonwealth Equity Services's Zevra Therapeutics position peaked at $276K in Q2 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.